The new drug, Latuda (lurasidone), will compete in a crowded market of "atypical" antipsychotics (Zyprexa, Abilify, Invega, etc)

The new drug, Latuda (lurasidone), will compete in a crowded market of "atypical" antipsychotics (Zyprexa, Abilify, Invega, etc)....

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote